The oncogenic/tumor-promoting role of ETS2 is supported by studies showing that a blockade of ETS2 not only reduces the transformed properties of DU145 and PC3 cells [13], but also induces apoptosis (reduced levels of the anti-apoptotic protein bcl-xL) and inhibits growth (reduced levels of cyclin D1 and c-Myc) [14], revealing a specific role of ETS2 in promoting the growth and survival of PCa cells. The gene discussed is BCL2L1; the disease is posterior cortical atrophy.